Navigation Links
miniTHERM CTT (120V / 60Hz)

ProductsminiTHERM CTT (120V / 60Hz)
Company Sartorius AG
Item miniTHERM CTT (120V / 60Hz)
Features 
Description A wide range of miniTHERM incubators is available, ensuring the customers to find the appropriate application solution for their specific requirements. miniTHERM incubators have a capacity of 18 liters, are compact and extremely space saving. Their size corresponds approximately to a typical microwave oven. It is possible to stack up to three units on top of each other. The units have a one-piece plastic casing. The inside corners have been rounded to make cleaning easy. This glass-like surface coating makes the interior easy to clean. The incubators are equipped with a digital temperature control unit and optional CO2 gassing.
This model, in addition to digitally regulated temperature and CO2 concentration, has an integral rotation mechanism. It is therefore ideally suited for cell culture in the miniPERM bioreactor. The integrated turning device provides space for a maximum of 6 miniPERM bioreactors. The turning speed can be adjusted from 0.1 to 20 rpm. Shelves with and without rollers are interchangeable. Consequently, it is possible to simultaneously incubate static cell culture flasks and rotating miniPERM bioreactors.
Info Sartorius AG
Customer Service: +49.551.308.0
Web site: http://www.sartorius.com/

Related medicine products :

1. miniTHERM T (230V / 50Hz)
2. miniTHERM CTT (230V / 50Hz)
3. miniTHERM T (120V / 60Hz)
4. miniPERM CT (120V / 60Hz)
5. CA-1000 (110V/60Hz)
6. BE-1200 (110V/60Hz)
7. Accucount 1000 (115V/60Hz)
8. Accucount 2000 (115V/60Hz)
9. Wellwash 4 Mk2 (110 -120 V AC/60Hz)
The HEMOCHRON Jr. Signature+ Microcoagulation System offers point-of-care monitoring with numerous features to meet the needs of each individual department, as well as the needs of regulatory complia
Inquire
...'000 tests per year through automatic scheduling a... processing up to 4 assays on 4 plates simultaneou...to presentation of the results, are controlled by ... tube rack) and 256 (POS-ID Linear Rack) samples c...
IMMULITE 2000 assays are designed for use with the IMMULITE 2000, a high-throughput, continuous random access immunoassay analyzer. IMMULITE 2000 offers testing efficiency through centralization, and
Medicine Products:
(Date:11/21/2008)...Call/ -- The Providence Service,Corporation (Nasd... the Company,s,Chief Operating Officer, has been ...r. Norris, appointment fills the vacancy left by t...nd returns the board to six members. Mr.,Norris ... Mr. Norris, age 41, has been with Providence ...
(Date:11/21/2008)...ainst Lennox-Gastaut syndrome , , FRIDAY...nzel (rufinamide) has been approved as a supplemen...d Lennox-Gastaut syndrome, the U.S. Food and Drug ... was based on results of a four-month clinical tri...o patients who took a placebo, those who took the ...
(Date:11/21/2008)...SNewswire/ -- New research at West Virginia Unive...tobacco product aimed at young adults is catching ...s, Camel Snus - touted as a socially acceptable wa...h levels of nicotine. , , "Camel Snus conta... said Bruce Adkins of the state Division of Tobacc...
(Date:11/21/2008)...wswire/ -- U.S. News & World Report and the Na...ed BlueChoice(R) HealthPlan of South Carolina in t...ublished in U.S. News & World Report,s issue t...ranks the nation,s best health plans based on clin...tation scores. NCQA and U.S. News & World Repo...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...n Parry, a 59 year old British grandmother is all ...India after undergoing a surgery// in the Indian c...ial Hospital has cured her of a painful back. Parr...to get the treatment on the UK’s National Health S...
...rwegian study has revealed that anti-depressants l...y inflict damage upon the human skeleton.// The No...NU) researcher Bjorn I. Gustafsson has revealed th...he activity of bone building cells, while raising ...
...archers at the University of North Carolina at Cha...aggressive prostate tumors. The molecule//, labele...ily and triggers aggressiveness in prostate tumors...recting cells to dump a tumor-suppressor protein. ...
...archers have found that exposure to pollutants inc...study was conducted on fisherman families eating//...nd pollutants known as Persistent Organochlorine P... biphenyls (PCBs) and DDT. Type 2 diabetes genera...
Other Medicine News:Health News:Indian Healthcare Facilities Come In For Praise 2
(Date:11/20/2008)...alif., Nov. 20 Bionovo, ... present results from the Phase 1B,clinical trial...tic breast,cancer, BZL101, at the Society for Int...e in Atlanta, Georgia. The Company,s oral present...will be presented as a part of the Best of the,SI...
(Date:11/20/2008)...20 PAREXEL International...iopharmaceutical services provider, today announce...ovide regulatory consulting and clinical research ..., PAREXEL now has locations throughout five import...ich also include Argentina, Brazil, Chile, and Mex...
(Date:11/19/2008)...tudy did not achieve statistical significance , ...l/ -- Pharmos Corporation (Nasdaq: PARS ) today ... of its topical NanoEmulsion (NE) drug delivery te...ine. , , The multi-center, randomized, doub... safety and efficacy of the Company,s 3% Diclofena...
(Date:11/19/2008)...Million Payment from Roche- , , MONTVALE, N...maceuticals Corp. (Nasdaq: MEMY ) today announce... Phase 2 trial of R3487/MEM 3454, its lead alpha-7...nt associated with schizophrenia (CIAS). The Comp...al, triggering a $5.0 million payment from its par...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Almost Family Reports Third Quarter 2008 Results 28817 1Almost Family Reports Third Quarter 2008 Results 28817 2Almost Family Reports Third Quarter 2008 Results 28817 3Almost Family Reports Third Quarter 2008 Results 28817 4Almost Family Reports Third Quarter 2008 Results 28817 5Almost Family Reports Third Quarter 2008 Results 28817 6Almost Family Reports Third Quarter 2008 Results 28817 7Almost Family Reports Third Quarter 2008 Results 28817 8Almost Family Reports Third Quarter 2008 Results 28817 9Almost Family Reports Third Quarter 2008 Results 28817 10Almost Family Reports Third Quarter 2008 Results 28817 11Almost Family Reports Third Quarter 2008 Results 28817 12Almost Family Reports Third Quarter 2008 Results 28817 13Almost Family Reports Third Quarter 2008 Results 28817 14Almost Family Reports Third Quarter 2008 Results 28817 15Almost Family Reports Third Quarter 2008 Results 28817 16InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 1InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 2InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 3InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 4InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 5InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 6InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 7InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 8InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 9InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 10InfuSystem Holdings Reports 14 5 25 Revenue Increase and Approximately 243 6 Million of Adjusted EBITDA for the Third Quarter of 2008 8899 11Neurobiological Technologies to Present at the Rodman 26 Renshaw 10th Annual Healthcare Conference in New York on November 10 8897 1Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 1Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 2Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 3Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 4Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 5Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs 8896 6
...E)--Apr 19, 2007 - Gilead Sciences, Inc.,(Nasdaq:G... III,AIR-CF2 study evaluating aztreonam lysine for...c fibrosis (CF) who have,pulmonary Pseudomonas aer...eatment course of aztreonam lysine significantly i...s (IV) antibiotics versus,placebo. All patients re...
... WIRE)--Apr 23, 2007 - CytRx Corporation,(NASDAQ:C...Ai),delivery technology exclusively licensed to it...orporation (RXi), has been,published in the April ... Chemical Biology. The technology was developed by...and University of,Massachusetts Medical School (UM...
Other Medicine Technology:Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4